

Table 13: Sensitivity analysis with adjustments made to the number of tumour measurements analysed.

		n	mean	95% CI	median	IQR	
ACTIVE	height	75	0.75	(0.65, 0.84)	0.65	(0.47 , 0.93)	
	Baseline	surface area	75	28.51	(24.94, 32.09)	26.45	(15.72 , 38.26)
		volume	75	7.66	(5.77, 9.54)	4.98	(2.79 , 9.20)
	Week 4	height	70	0.79	(0.69, 0.90)	0.66	(0.49 , 1.01)
		surface area	70	29.15	(25.35, 32.94)	27.69	(15.18 , 38.81)
		volume	70	8.36	(6.13, 10.59)	5.03	(2.81 , 9.47)
	Week 12	height	70	0.79	(0.69, 0.90)	0.67	(0.49 , 1.02)
		surface area	70	29.20	(25.42, 32.98)	26.99	(18.30 , 39.76)
		volume	70	8.40	(6.19, 10.61)	4.91	(2.85 , 9.48)
PLACEBO	height	75	0.74	(0.65, 0.83)	0.62	(0.48 , 0.91)	
	Baseline	surface area	75	28.74	(24.22, 33.25)	24.81	(15.45 , 35.07)
		volume	75	8.26	(5.63, 10.89)	4.57	(2.37 , 8.98)
	Week4	height	70	0.77	(0.66, 0.89)	0.65	(0.47 , 0.96)
		surface area	70	29.25	(24.29, 34.22)	25.32	(15.11 , 35.10)
		volume	70	9.18	(5.89, 14.46)	4.89	(1 , 7.90)
	Week 12	height	70	0.77	(0.67, 0.88)	0.66	(0.47 , 0.99)
		surface area	70	29.16	(24.15, 34.16)	25.52	(14.88 , 35.92)
		volume	70	9.03	(5.71, 12.34)	4.80	(2.11 , 8.26)

In two patients active ointment was found in tumours that should have been treated with placebo and no trace of active ointment in the tumours that should have been treated with the active ointment. It has been assumed that these patients have been applying ointment in the opposite way to which they were supposed to. The table of descriptive tumour measurements has been repeated with these patients allocated to the treatment they received rather than that which they were randomised to